Author(s): Koppala RVS Chaitanya, Venna R Surya Anusha

Email(s): koppala526@gmail.com

DOI: 10.52711/0974-360X.2022.00679   

Address: Koppala RVS Chaitanya1*, Venna R Surya Anusha2
1Department of Pharmacology, Vignan Institute of Pharmaceutical Technology, Kapujaggraju Peta, Visakhapatnam, Andhra Pradesh, India, 530049.
2AU College of Pharmaceutical Sciences, Andhra University, Visakhapatnam, Andhra Pradesh, India, 530003.
*Corresponding Author

Published In:   Volume - 15,      Issue - 9,     Year - 2022


ABSTRACT:
Nipah Virus (NiV), that remained anonymous till 1999 turned to be an alarming zoonotic virus since the Malaysian outbreak, showing a specific case fatality ranging from 40-70%. With a broad spectrum of genus susceptibility and Fruit bats (Microchiroptera) as their natural hosts, NiVarose endemic with yearly outbreaks in some regions like Bangladesh. General symptoms of infection i.e., illness, fever, headache, and drowsiness may also lead to long-term neurological defects like encephalitis, coma, and death. Though diagnostic developments aided in early and accurate diagnosis of NiV infection giving a chance of treatment at the earliest possible (before worsening), there is no approved drug or vaccine for NiV treatment. Inclusion of Nipah Virus in WHO R&D Blueprint list of priority diseases 2018 once again emphasized the emergency to hasten the research on NiV therapeutics. It took twenty years to take the initial step of vaccine development. CIPE announcement on vaccine entering phase 1 clinical trials initiated hope for the vaccine soon. This review provides an understanding of NiV structural proteins and their importance in viral assembly, replication, and evasion during NiV infection and their role in predicting and designing potential therapeutic targets. Further, it highlighted the hitches encountered in designing possible therapeutic agents and efforts to confront them.


Cite this article:
Koppala RVS Chaitanya, Venna R Surya Anusha. Recapitulation of Nipah Virus Disease: Multiple strategies for future therapeutics. Research Journal of Pharmacy and Technology. 2022; 15(9):4048-4. doi: 10.52711/0974-360X.2022.00679

Cite(Electronic):
Koppala RVS Chaitanya, Venna R Surya Anusha. Recapitulation of Nipah Virus Disease: Multiple strategies for future therapeutics. Research Journal of Pharmacy and Technology. 2022; 15(9):4048-4. doi: 10.52711/0974-360X.2022.00679   Available on: https://rjptonline.org/AbstractView.aspx?PID=2022-15-9-39


REFERENCES:
1.    Hayman D. T. Johnson N. Nipah Virus: a virus with multiple pathways of emergence. In The Role of Animals in Emerging Viral Diseases. 2014; 293-315. Academic Press.
2.    Chua KB. Nipah virus outbreak in Malaysia. Journal of Clinical Virology. 2003; 26(3):265-275.
3.    Michael D. Jane G. A Taste For Pork Helped A Deadly Virus Jump To Humans. Available at: https://www.npr.org/sections/goatsandsoda/2017/02/25/515258818/a-taste-for-pork-helped-a-deadly-virus-jump-to-humans. Accessed on 16 June 2019.
4.    Paden CR. Yusof MFBM. Al Hammadi ZM. Queen K. Tao Y. Eltahir YM. Al Muhairi SSM. Zoonotic Origin and Transmission of Middle East Respiratory Syndrome Coronavirus in the UAE. Zoonoses and public health. 2018; 65(3):322-333.
5.    Food and Agriculture Organization of The United Nations. Nipah Virus. Available at: http://www.fao.org/ag/againfo/programmes/en/empres/nipah/index.html. Accessed on 18 June 2019.
6.    Tan KS. Tan CT. Goh KJ. Epidemiological Aspects of Nipah Virus Infection. Neurol J Southeast Asia. 1999: 4(1):77-81.
7.    World Health Organization, Nipah virus. Available at: https://www.who.int/news-room/fact-sheets/detail/nipah-virus. Accessed on 20 July 2019.
8.    World Health Organization. Nipah virus in Bangladesh. Available at: https://www.who.int/csr/don/2004_04_20/en/ Accessed on 20 July 2019.
9.    Deka MA. Morshed N. Mapping Disease Transmission Risk of Nipah Virus in South And Southeast Asia. Tropical medicine and infectious disease. 2018; 3(2):57.
10.    Venkatesan G. Balamurugan V. Gandhale PN. Singh RK. Bhanuprakash V. Viral Zoonosis: A Comprehensive Review. Asian Journal of Animal and Veterinary Advances. 2010; 5(2):77-92.
11.    Gurley ES. Montgomery JM. Hossain MJ. Bell M. Azad AK. Islam MR. Breiman RF. et al. Person-To-Person Transmission Of Nipah Virus In A Bangladeshi Community. Emerging Infectious Diseases. 2007; 13(7):1031.
12.    Kulkarni, DD. Tosh C. Venkatesh G. Kumar DS. Nipah Virus Infection: Current Scenario. Indian Journal of Virology, 2013; 24(3):398-408.
13.    Giangaspero M. Nipah Virus. Tropical Medicine and Surgery. 2013; 1(129):1-8.
14.    Tan DS. Some Zoonotic Diseases Prevalent In Malaysia. The Malaysian journal of pathology. 1981; 4:19-27.
15.    Epstein JH. Field HE. Luby S. Pulliam JR. Daszak P. Nipah Virus: Impact, Origins, and Causes of Emergence. Current Infectious Disease Reports. 2006; 8(1):59-65.
16.    Pavlovich SS. Lovett SP. Koroleva G. Guito JC. Arnold CE. Nagle ER. et al. The Egyptian Rousette Genome Reveals Unexpected Features Of Bat Antiviral Immunity. Cell. 2018; 173(5):1098-1110.
17.    Kitsutani P. Ohta M. Nipah Virus Infections. Nihon Rinsho. Japanese journal of clinical medicine. 2005; 63(12):2143-2153.
18.    The Economic Times. Nipah Virus: Symptoms, prevention, treatment of the infection. Available at: https://economictimes.indiatimes.com/magazines/panache/throbbing-headache-nausea-facts-symptoms-prevention-of-nipah-virus/articleshow/64285621.cms. Accessed on 01 June 2018.
19.    World Organization for Animal Health. Nipah Virus General Disease Information Sheet. Available at: https://www.oie.int/en/animal-health-in-the-world/animal-diseases/Nipah-Virus/. Accessed on 18 December 2019.
20.    Plowright RK. Becker DJ. Crowley DE. Washburne AD. Huang T. Nameer PO. Gurley ES. Han BA. Prioritizing Surveillance of Nipah Virus in India. PLoS neglected tropical diseases. 2019; 13(6):e0007393. https://doi.org/10.1371/journal.pntd.0007393.
21.    Food and Agriculture Organization of The United Nations. The Emergence of Nipah Virus, In Manual On The Diagnosis of Nipah Virus Infection In Animal. Bangkok, Thailand. 2002. Available at: http://www.fao.org/3/ah690e/ah690e00.pdf. Accessed on 18 June 2019.
22.    Center for food security and public health, Nipah virus. Available at: http://www.cfsph.iastate.edu/DiseaseInfo/disease.php?name=nipah&lang=en. Accessed on 18 December 2019.
23.    Rockx B. Winegar R. Freiberg AN. Recent Progress in Henipavirus Research: Molecular Biology, Genetic Diversity, Animal Models. Antiviral research. 2012; 95(2):135-149.
24.    Bonaparte MI. Dimitrov AS. Bossart KN. Crameri G. Mungall BA. Bishop KA et al. Broder. Ephrin-B2 Ligand Is A Functional Receptor For Hendra Virus And Nipah Virus. Proceedings of the National Academy of Sciences. 2005; 102(30):10652-10657.
25.    Bruhn JF. Barnett KC. Bibby J. Thomas JM. Keegan RM. Rigden DJ. et al. Crystal Structure of The Nipah Virus Phosphoproteintetramerization Domain. Journal of virology, 2014; 88(1):758-762.
26.    Omi-Furutani M. Yoneda M. Fujita K. Ikeda F. Kai C. Novel Phosphoprotein-Interacting Region in Nipah Virus Nucleocapsid Protein And Its Involvement In Viral Replication. Journal of virology. 2010; 84(19):9793-9799.
27.    Jordan PC. Liu C. Raynaud P. Lo MK. Spiropoulou CF. Symons JA. Initiation, Extension, and Termination of RNA Synthesis by A Paramyxovirus Polymerase. PLoS pathogens. 2018; 14(2):e1006889.
28.    Watkinson RE. Lee B. Nipah Virus Matrix Protein: Expert Hacker of Cellular Machines. FEBS letters. 2016; 590(15):2494-2511.
29.    Dietzel E. Kolesnikova L. Sawatsky B. Heiner A. Weis M. Kobinger GP. Nipah Virus Matrix Protein Influences Fusogenicity and Is Essential For Particle Infectivity and Stability. Journal of Virology. 2016; 90(5):2514-2522.
30.    Yoneda M. Guillaume V. Sato H. Fujita K. Georges-Courbet MC. Ikeda F. Omi M. Muto-Terao Y. Wild TF. Kai C. The Nonstructural Proteins Of Nipah Virus Play A Key Role In Pathogenicity In Experimentally Infected Animals. PLoS One. 2010; 5(9):e12709.
31.    Hughes JM. Wilson ME. Luby SP. Gurley ES. Hossain MJ. Transmission of Human Infection with Nipah Virus. Clinical Infectious Diseases. 2009; 49(11):1743-1748.
32.    World Animal Health Information System (WAHiS) - Wild Interface. Available at: http://www.oie.int/wahis_2/public/wahidwild.php/Diseaseinformation/Diseasesituation. Accessed on 30 December 2018.
33.    Guillaume V. Contamin H. Loth P. Georges-Courbot MC. Lefeuvre A. Marianneau P. Nipah Virus: Vaccination and Passive Protection Studies In a Hamster Model. Journal of virology. 2004; 78(2):834-840.
34.    Mathieu C. Pohl C. Szecsi J. Trajkovic-Bodennec S. Devergnas S. Raoul H. Cosset FL. Gerlier D. Wild TF. Horvat B. Nipah Virus Uses Leukocytes for Efficient Dissemination within a Host. Journal of virology. 2011; 85(15):7863-7871.
35.    Han HJ. Yu H. Yu XJ. Evidence for Zoonotic Origins of Middle East Respiratory Syndrome Coronavirus. The Journal of general virology. 2016; 97: 274-280.
36.    Ang BS. Lim TC. Wang L. Nipah Virus Infection. Journal of clinical microbiology. 2018; 56(6); e01875-17.
37.    Hefferon KL. Applications of Plant-Derived Vaccines for Developing Countries. Tropical Medicine & Surgery. 2013;1-4.
38.    Johnston SC. Briese T. Bell TM. Pratt WD. Shamblin JD. Esham HL. et al. Detailed Analysis Of The African Green Monkey Model of Nipah Virus Disease. PloS one. 2015; 10(2). e0117817.
39.    Middleton D. Pallister J. Klein R. Feng YR. Haining J. Arkinstall, R. Hendra Virus Vaccine, A One Health Approach To Protecting Horse, Human, and Environmental Health. Emerging infectious diseases. 2014; 20(3):372-379.
40.    Prescott J. DeBuysscher BL. Feldmann F. Gardner DJ. Haddock E. Martellaro C. et al. Single-Dose Live-Attenuated Vesicular Stomatitis Virus-Based Vaccine Protects African Green Monkeys From Nipah Virus Disease. Vaccine. 2015; 33(24):2823-2829.
41.    Kamthania M. Sharma DK. Epitope-Based Peptides Prediction from Proteome of Nipah Virus. International Journal of Peptide Research and Therapeutics. 2016; 22(4):465-470.
42.    Mohammed AA. Shantier SW. Mustafa MI. Osman HK. Elmansi HE. Osman IAA. et al. Epitope-Based Peptide Vaccine Against Glycoprotein G of Nipah Henipavirus Using Immunoinformatics Approaches. Journal of Immunology Research. 2020.
43.    Sazzad HM. A Trial for Post-Exposure Prophylaxis against Henipaviruses. The Lancet. Infectious diseases. 2020; 20(4):387-388.
44.    Bossart KN. Zhu Z. Middleton D. Klippel J. Crameri G. Bingham J. A Neutralizing Human Monoclonal Antibody Protects Against Lethal Disease In A New Ferret Model of Acute Nipah Virus Infection. PLoSPathog. 2009; 5(10):e1000642.
45.    Geisbert TW. Mire CE. Geisbert JB. Chan YP. Agans KN. Feldmann F. et al. Therapeutic Treatment of Nipah Virus Infection In Nonhuman Primates With A Neutralizing Human Monoclonal Antibody. Science translational medicine. 2014; 6(242):1-16.
46.    Playford EG. Munro T. Mahler SM. Elliott S. Gerometta M. Hoger KL. et al. Safety, Tolerability, Pharmacokinetics, And Immunogenicity of A Human Monoclonal Antibody Targeting The G Glycoprotein Of Henipaviruses In Healthy Adults: A First-In-Human, Randomised, Controlled, Phase 1 Study. The Lancet Infectious Diseases. 2020;445-454.
47.    Banerjee S. Niyas VKM. Soneja M. Shibeesh AP. Basheer M. Sadanandan R. et al. First Experience of Ribavirin Postexposure Prophylaxis For Nipah Virus, Tried During The 2018 Outbreak In Kerala, India. Journal of Infection. 2019; 78(6);491-503.
48.    Chong HT. Kamarulzaman A. Tan CT. Goh KJ. Thayaparan T. Kunjapan SR. et al. Treatment of Acute Nipah Encephalitis with Ribavirin. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society. 2001; 49(6):810-813.
49.    Dawes BE. Kalveram B. Ikegami T. Juelich T. Smith JK. Zhang L. et al. Favipiravir (T-705) Protects Against Nipah Virus Infection In The Hamster Model. Scientific reports. 2018; 8(1):1-11.
50.    Goldhill DH. TeVelthuis AJ. Fletcher RA. Langat P. Zambon M. Lackenby A. Barclay, WS. The Mechanism of Resistance to Favipiravir in Influenza. Proceedings of the National Academy of Sciences. 2018; 115(45):11613-11618.
51.    Sen N. Kanitkar TR. Roy AA. Soni N. Amritkar K. Supekar S. et al. Predicting and Designing Therapeutics against the Nipah Virus. PLoS neglected tropical diseases. 2019; 13(12):e0007419.
52.    CEPI. CEPI-funded Nipah Virus Vaccine Candidate First to Reach Phase 1 Clinical Trial, 13 march 2020. Available at: https://cepi.net/news_cepi/cepi-funded-nipah-virus-vaccine-candidate-first-to-reach-phase-1-clinical-trial/. Accessed on 5 April 2020.
53.    NIH. U.S. National Library of Medicine, ClinicalTrials.gov, Safety, and Immunogenicity of a Nipah Virus Vaccine. Available at: https://clinicaltrials.gov/ct2/show/NCT04199169. Accessed on 8th April 2020.
54.    Chua KB. Epidemiology, surveillance and control of Nipah virus infections in Malaysia. The Malaysian journal of pathology. 2010; 32(2): 69-73.
55.    WHO. Nipah virus - India. World Health Organization, 31 may, 2018. Available at: https://www.who.int/csr/don/31-may-2018-nipah-virus-india/en/. Accessed on 24 Feb 2019.
56.    WHO, Nipah virus - India. World Health Organization, 07 August 2018. Available at: https://www.who.int/csr/don/07-august-2018-nipah-virus-india/en/. Accessed on 24 Feb 2019.
57.    WHO, Nipah virus - India. World Health Organization, 07 August 2018. Available at: https://www.who.int/csr/don/31-may-2018-nipah-virus-india/en/. Accessed on 24 Feb 2019.
58.    P. Nataraj. Manipal Virologist First to Reveal the Nipah Virus Outbreak. Deccan Herald, 25 May 2018.
59.    SEARO2018. Programs and Projects, Surveillance, and Outbreak Alert: Outbreak of Nipah Virus Encephalitis in The Kerala State Of India. World health organization Southeast Asia, 2018. 8 June.

Recomonded Articles:

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

0.38
2018CiteScore
 
56th percentile
Powered by  Scopus


SCImago Journal & Country Rank


Recent Articles




Tags


Not Available